Keyphrases
Anticoagulant Therapy
100%
Sickle Cell Disease
83%
Coagulation
41%
Factor Xa Inhibitors
33%
Endothelial Activation
33%
University of North Carolina
27%
Inflammation
27%
Hemoglobinopathies
27%
End-organ Disease
16%
Coagulation Proteases
16%
Vascular Pathology
16%
Targeted Inhibition
16%
Rivaroxaban
16%
Coagulation Pathway
16%
Protease-activated Receptor 1 (PAR1)
16%
Anticoagulation
16%
Hemoglobin Disorders
16%
Vascular Occlusion
16%
Therapeutic Potential
13%
Research Awards
13%
Multidisciplinary Team
13%
Research Career
13%
New Therapies
13%
Mouse Model
13%
Career Development
13%
Training Research
13%
Coagulation Cascade
13%
New Discovery
13%
Academic Environment
13%
Chapel Hill
13%
Clinical Trials
13%
Mechanistic Studies
13%
Basic Scientist
13%
Tissue Factor
13%
Clinical Investigator
13%
Medicine and Dentistry
Anticoagulant Therapy
100%
Sickle-Cell Disease
83%
Patient with Sickle Cell Disease
50%
Proteinase Activated Receptor 2
50%
Hemoglobinopathy
41%
Thromboplastin
25%
Proteinase Activated Receptor 1
25%
Vascular Occlusion
25%
Blood Clotting Factor 10a Inhibitor
25%
Rivaroxaban
25%
Prothrombinase
25%
Anticoagulation
20%
Pathophysiology
20%
Clinical Trial
20%
Disease
20%
Doctor of Philosophy
20%
Clinical Study
20%
Proteinase
20%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
100%
Sickle Cell Anemia
83%
Proteinase Activated Receptor 2
33%
Hemoglobinopathy
33%
Inflammation
27%
Thromboplastin
16%
Rivaroxaban
16%
Blood Vessel Occlusion
16%
Blood Clotting Factor 10a Inhibitor
16%
Proteinase Activated Receptor 1
16%
Clinical Trial
13%
Disease
13%
Blood Clotting Factor 10a
13%
Pathophysiology
13%
Proteinase
13%
Preclinical Study
13%
Mouse Model
13%